UC San Diego neurobiologists identify specific brain circuitry responsible for placebo pain relief using novel mouse models

UC San Diego researchers map the neural pathways behind placebo pain relief, discovering how the brain produces its own broad-spectrum painkillers.

By: AXL Media

Published: Apr 17, 2026, 7:06 AM EDT

Source: Information for this report was sourced from University of California - San Diego

Decoding the Neurological Mechanisms of Expectancy Driven Relief

Neurobiologists at the University of California San Diego have reached a significant milestone in understanding how the brain generates relief without active medication. The study, published in the journal Neuron, utilizes a reverse translation method to map the circuitry behind the placebo effect. By adapting human placebo protocols for use in mice, researchers identified specific regions in the cortex that link to the brainstem and spinal cord to modulate pain. According to Associate Professor Matthew Banghart, this approach allowed the team to deconstruct the underlying mechanisms and pinpoint exactly where the brain’s own signals act to suppress suffering.

Identifying the Hub for Endogenous Opioid Signaling

The research team focused on a specific region known as the ventrolateral periaqueductal gray, or vlPAG, which serves as a central hub for pain signaling. Using advanced sensors developed in collaboration with UC Davis and the Max Planck Florida Institute, the scientists detected the release of endorphins—natural opioid neuropeptides—during placebo trials. According to the study, these native peptides are critical for driving the pain-relieving effects associated with the placebo response. This discovery provides the first clear evidence of a specific site where the body’s internal chemistry replicates the effects of external painkillers to manage discomfort.

Advanced Optical Tools Validate Internal Pain Suppression

To confirm that these naturally occurring opioids were truly responsible for the relief, the researchers employed a light-activated drug called PhNX, or photoactivatable naloxone. This technology allowed the team to use light to precisely block opioid signaling in the vlPAG at specific times. The experiment revealed that when this signaling was interrupted, both morphine-induced and placebo-induced pain relief were neutralized. According to Banghart, this validates that the placebo effect relies on the same chemical pathways as high-strength pharmaceutical opioids but is triggered internally through learned expectation.